DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation
- Posted on October 23, 2025
- By Google News
- 1 Views
DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation
DefenCath, first and only FDA‑approved antimicrobial CLS in the US, receives Vizient Innovative Technology designation. Phase 3 showed 71% CRBSI risk reduction.
